Abstracts tagged "IL-6"

Abstract Number: 1208 • ACR Convergence 2021
Composite Articular Index Including Acute Phase Reactants Should Not Be Used in Patients with Rheumatoid Arthritis Treated with Il6 Inhibitors but May Be Useful in Those Receiving Jak Inhibitors: Ultrasound Evidence
Andrés Ponce¹, Beatriz Frade-Sosa², Ramirez Julio³, Núria Sapena¹, Roberto Gumucio², Virginia Ruiz-Esquide², Rosa Morlà², Marta Bassas², Juan D Cañete⁴ and Jose A Gomez-Puerta², ¹Rheumatology Department, Hospital Clínic, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital Universitari Clinic, Barcelona, Spain, ⁴Rheumatology Department, Hospital Clinic, Barcelona, Spain
Background/Purpose: IL6 inhibitors (IL6i) have a dramatic effect on the reduction of C reactive protein (CRP) that does not always correlate with a significant improvement…
Abstract Number: 1976 • 2019 ACR/ARP Annual Meeting
Regulation of Interleukin-1β (IL-1β)-induced COX-2 Expression and IL-6 and MMP-1 Production in Human OA Synovial Fibroblasts by Guanylate Binding Protein 5
Mahamudul Haque¹, Madeline McDougal ¹, Anil Singh ¹ and Salahuddin Ahmed ², ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, SPOKANE, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA
Background/Purpose: Osteoarthritis (OA) is a chronic degenerative joint disease caused by synovial inflammation and cartilage degradation primarily driven by interleukin-1beta (IL-1β). Studies suggest that TNF-stimulated…
Abstract Number: 2351 • 2019 ACR/ARP Annual Meeting
Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis
Jeffrey Curtis¹, Yong Lin ², Karthinathan Thangavelu ³, Marina Stanislav ⁴, Gregory St John ⁵, Antonio Gómez-Centeno ⁶, Carlo Selmi ⁷, Thomas Huizinga ⁸, José Antonio Maldonado-Cocco ⁹, Marwan Bukhari ¹⁰ and Frank Buttgereit ¹¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sanofi, Bridgewater, NJ, ³Sanofi Genzyme, Boston, MA, ⁴V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Corporació Sanitària Parc Taulí, Barcelona, Spain, ⁷Humanitas Research Hospital, University of Milan, Milan, Italy, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Buenos Aires University School of Medicine, Buenos Aires, Argentina, ¹⁰Lancaster University Medical School, Lancaster, United Kingdom, ¹¹Charité-Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The EXTEND open-label extension study (NCT01146652) is collecting data on long-term treatment of RA with sarilumab as monotherapy and in combination with conventional synthetic…
Abstract Number: 2392 • 2019 ACR/ARP Annual Meeting
The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis
Takayasu Ando¹, Takeshi Suzuki ², Yutaka Gotou ¹ and Kimito Kawahata ³, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ²Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan
Background/Purpose: In daily practice, our rheumatologist has experienced different clinical feature of elderly-onset rheumatoid arthritis (EORA) compared with younger-onset RA (YORA). In EORA patients, serological…
Abstract Number: 2493 • 2019 ACR/ARP Annual Meeting
IL-6 and TNF-α Influence on Clinical Manifestations, Activity and Comorbidity in Psoriatic Arthritis Patients
Maria Elisa Acosta¹, Luis Gomez-Lechon ¹, Guadalupe Manzano Canabal ¹, Olga Compan ², Cristina Hidalgo ³, Olga Martinez ¹, Ana Turrión ¹, Javier del Pino ¹ and Carlos Montilla ¹, ¹Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²Hospital Clinico Universitario de Salamanca, SALAMANCA, Spain, ³Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain
Background/Purpose: The activation of the Th-1 and Th-17 lymphocytes response seems to be one of the causes associated with PsA onset. During this process cytokines…
Abstract Number: 2494 • 2019 ACR/ARP Annual Meeting
Comparison of Comorbidity in Spondyloarthritis: Influence on Inflammatory Activity in Patients with Psoriatic Arthritis
Luis Gomez-Lechon¹, Maria Elisa Acosta ¹, Guadalupe Manzano Canabal ¹, Olga Compan ¹, Cristina Hidalgo ², Olga Martinez ¹, Ana Turrión ¹, Javier del Pino ¹ and Carlos Montilla ¹, ¹Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease that is included in the group of spondyloarthritis. Although PsA has its own clinical characteristics, it has…
Abstract Number: 1 • 2019 ACR/ARP Annual Meeting
Interleukin-6 Promotes Osteoclast-like Phenotype in Human Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh¹, Mahamudul Haque ¹, Bhanupriya Madarampalli ² and Salahuddin Ahmed ³, ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, Spokane, WA, ²University of Washington, Seattle, WA, ³Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation and joint destruction caused by pro-inflammatory cytokines. Progressive joint damage is also an…
Abstract Number: 1387 • 2019 ACR/ARP Annual Meeting
Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab
Jeffrey Curtis¹, Daniel Aletaha ², Gerd Burmester ³, Kerri Ford ⁴, Hubert van Hoogstraten ⁵, Henry Leher ⁶, Karthinathan Thangavelu ⁷ and Vivian Bykerk ⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Medical University of Vienna, Vienna, Austria, ³Charité—University Medicine Berlin, Berlin, Germany, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁷Sanofi Genzyme, Boston, MA, ⁸Hospital for Special Surgery, New York City, NY
Background/Purpose: Guidelines recommend adjusting therapy in patients with RA who fail to reach low disease activity or remission. Partial responders to a TNF inhibitor may…
Abstract Number: 1393 • 2019 ACR/ARP Annual Meeting
Impact of Sarilumab on Unacceptable Pain and Inflammation Control in Moderately-to-Severely Active Rheumatoid Arthritis (RA) Patients in 3 Phase 3 Studies
Vivian Bykerk¹, Wenhui Wei ², Susan Boklage ², Toshio Kimura ², Stefano Fiore ³ and Gregory St John ⁴, ¹Hospital for Special Surgery, New York City, NY, ²Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Pain, a core-set domain and a troubling symptom to patients with RA, may be directly related to inflammation. Unacceptable pain (UP) levels may persist…
Abstract Number: 1707 • 2019 ACR/ARP Annual Meeting
IL-6 Promotes IgG4-related Disease by Inducing Fibroblast-dependent Tfh Cell and B Cell Differentiation Factors
Zongfei Ji¹, Rongyi Chen ², Xiaomeng Cui ², Lili Ma ², Xiufang Kong ³, Lingying Ma ², Ying Sun ², Xiaomin Dai ², Zhuojun Zhang ², Huiyong Chen ² and Lindi Jiang ², ¹Department of Rheumatology, Zhongshan hospital, Fudan University, Shanghai, China (People's Republic), ²Zhongshan hospital, Fudan University, Shanghai, China (People's Republic), ³University of Michigan & Fudan University, Ann Arbor, MI
Background/Purpose: Considering the unsatisfied effect of conventional therapy, to investigate the pathogenesis of IgG4-related disease (IgG4-RD) is crucial to explore novel treatment strategies. This study…
Abstract Number: L08 • 2018 ACR/ARHP Annual Meeting
High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response
Anita Boyapati¹, Jérôme Msihid², Sergio Schwartzman³, Ernest Choy⁴, Mark C. Genovese⁵, Gerd R. Burmester⁶, Gordon Lam⁷, Toshio Kimura¹, Jonathan Sadeh⁸ and Neil M.H. Graham¹, ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Sanofi Chilly-Mazarin, Chilly-Mazarin, NJ, France, ³Hospital for Special Surgery, New York, NY, ⁴CREATE Center, Cardiff University School of Medicine, Cardiff, Great Britain, ⁵Division of Immunology & Rheumatology, Stanford University, Stanford, CA, ⁶Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ⁷Atrium Health, Charlotte, NC, ⁸Sanofi, Bridgewater, NJ
Background/Purpose: Clinical application of biomarkers to predict response to therapy is the next frontier in RA. Despite the key role of IL-6 in RA, the…
Abstract Number: 1528 • 2018 ACR/ARHP Annual Meeting
Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
Gerd R. Burmester¹, Owen Hagino², Qunming Dong³, Marina Stanislav⁴, Antonio Gomez-Centeno⁵, Carlo Selmi⁶, Tom W.J. Huizinga⁷, Erin Mangan⁸, Cem Gabay⁹ and Mark C. Genovese¹⁰, ¹Charité – University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²Sanofi Genzyme, Bridgewater, NJ, ³Sanofi, Bridgewater, NJ, ⁴Scientific Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russian Federation, ⁵Corporació Sanitària Parc Taulí, Barcelona, Spain, ⁶Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁹University Hospitals of Geneva, Geneva, Switzerland, ¹⁰Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Anemia (WHO criteria: Hemoglobin [Hb] levels <12.0 g/dL [females] or <13.0 g/dL [males]) is a common finding associated with increased joint inflammation in patients…
Abstract Number: 1550 • 2018 ACR/ARHP Annual Meeting
Improvement of HbA1c in Patients with Rheumatoid Arthritis and Diabetes Type 2 during Treatment with Tocilizumab
Christof Specker¹, Annette Alberding², Martin Aringer³, Gerd R. Burmester⁴, Jan-Paul Flacke⁵, Michael Hofmann⁶, Peter Kaestner⁷, Herbert Kellner⁸, Frank Moosig⁹, Maren Sieburg¹⁰, Hans-Peter Tony¹¹ and Gerhard Fliedner¹², ¹Rheumatology and Clinical Immunology, Universitätsklinikum Essen, Essen, Germany, ²Internal Rheumatology, Krankenhaus St. Josef, Wuppertal, Germany, ³Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ⁴Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁵Rheumatology, Roche Pharma AG, Grenzach-Wyhlen, Germany, ⁶Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ⁷Rheumatology, Ambulantes Rheumazentrum, Erfurt, Germany, ⁸Ambulantes Rheumazentrum, Erfurt, Germany, ⁹Rheumatology Center Schleswig-Holstein Mitte, Neumuenster, Germany, ¹⁰Rheumatologische Gemeinschaftspraxis, Magdeburg, Germany, ¹¹Rheumatology/Immunology, Medizinische Klinik II, Universitätsklinik, Würzburg, Germany, ¹²Rheumatological Practice, Osnabrueck, Germany
Background/Purpose: Interleukin 6 (IL-6) and C-reactive protein (CRP) are independent risk factors for type 2 diabetes mellitus [1], and IL-6 plays a role in insulin…
Abstract Number: 1940 • 2018 ACR/ARHP Annual Meeting
Reductions in Absolute Neutrophil Count (ANC) with Sarilumab Resulting in Dose Delays or Dose Decreases: Effects on Efficacy and Safety
Jeffrey R. Curtis¹, Gregory St. John², Michael Pannucci², Yong Lin³, José A. Maldonado-Cocco⁴, Tom W.J. Huizinga⁵, Marina Stanislav⁶ and Paul Emery⁷, ¹University of Alabama, Birmingham, AL, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Universidad de Buenos Aires, Buenos Aires, Argentina, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russian Federation, ⁷University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: In sarilumab randomized controlled trials (RCTs), dose delay and/or reduction was recommended for management of patients who developed neutropenia Grade (G) 3 (ANC ≥500…
Abstract Number: 1963 • 2018 ACR/ARHP Annual Meeting
Phenome Wide Association Study of IL6R Variant Identifies Drug Target for Cardiovascular Disease and Inflammation
Tianxi Cai^1,2,3, Yichi Zhang^1,3, Yuk-Lam Ho¹, Nicholas Link¹, Jiehuan Sun^1,3, Jie Huang^1,4, Tianrun Cai^1,2,4, Scott Damrauer⁵, Yuri Ahuja², Jacqueline Honerlaw¹, Jie Huang¹, Lauren Costa¹, Petra Schubert¹, Chuan Hong³, David Gagnon^1,6, Yan Sun⁷, Michael Gaziano^1,2,4, Peter Wilson^7,8, Kelly Cho^1,2,4, Philip Tsao⁹, Christopher J. O'Donnell^1,2 and Katherine P. Liao^1,2,4, ¹VA Boston Healthcare System, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Corporal Michael Crescenz VA Medical Center, Perlman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Boston University School of Public Health, Boston, MA, ⁷Emory University Schools of Medicine and Public Health, Atlanta, GA, ⁸Atlanta VA Medical Center, Atlanta, GA, ⁹VA Palo Alto Health Care System, Department of Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Individuals with an interleukin 6 receptor (IL6R) genetic variant not on IL6R blocking therapy have biomarker profiles similar to those treated with IL6R blockers. …

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].